De Vito C, Papathomas GT, Pedica F, Kane P, Amir A, Heaton N, Quaglia A

Idioma: Ingles.
Referencias bibliográficas: 28
Paginas: 263-268
Archivo PDF: 308.92 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43: 515-24.

2. Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, et al. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology 2017; 152: 880-6.

3. Pilati C, Zucman-Rossi J. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine Growth Factor Rev 2015; 26: 499-506.

4. Calderaro J, Nault JC, Balabaud C, Couchy G, Saint Paul MC, Azoulay D, Mehdaoui D, et al. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. Mod Pathol 2016; 29: 43-50.

5. Wang H-W, Pittaluga S, Jaffe ES. Multicentric Castleman disease: Where are we now? Semin Diagn Pathol 2016 May 16. doi: 10.1053/j.semdp.2016.05.006

6. Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol 2016; 3: e163-75.

7. Sipe JD, Benson MD, Buxbaum JN, Ikeda S-I, Merlini G, Saraiva MJM, Westermark P. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014; 21: 221-4.

8. Ganapathi MK, May LT, Schultz D, Brabenec A, Weinstein J, Sehgal PB, Kushner I. Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophys Res Commun 1988; 157: 271-7.

9. Chandan VS, Shah SS, Lam-Himlin DM, Petris GD, Mereuta OM, Dogan A, Torbenson MS, et al. Globular hepatic amyloid is highly sensitive and specific for LECT2 amyloidosis. Am J Surg Pathol 2015; 39: 558-64.

10. Iwata T, Hoshii Y, Kawano H, Gondo T, Takahashi M, Ishihara T, Yokota T, et al. Hepatic amyloidosis in Japan: histological and morphometric analysis based on amyloid proteins. Hum Pathol 1995; 26: 1148-53.

11. Morita-Hoshi Y, Tohda S, Miura O, Nara N. An autopsy case of multicentric Castleman’s disease associated with interstitial nephritis and secondary AA amyloidosis. Int J Hematol 2008; 87: 69-74.

12. Ordi J, Grau JM, Junqué A, Nomdedeu B, Palacin A, Cardesa A. Secondary (AA) amyloidosis associated with Castleman’s disease. Report of two cases and review of the literature. Am J Clin Pathol 1993; 100: 394-7.

13. Yamagata N, Fujio J, Hirai R, Matsumaru M, Tanimura S, Inokuchi C, Shikai T, et al. Marked hepatomegaly due to AA type amyloidosis in a case with Castleman’s disease. Int J Hematol 2006; 84: 70-3.

14. Shimojima Y, Takei Y-I, Tazawa K-I, Gono T, Fushimi T, Matsuda M, Hoshii Y, et al. Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman’s disease. Amyloid 2006; 13: 184-6.

15. Gaduputi V, Tariq H, Badipatla K, Ihimoyan A. Systemic Reactive Amyloidosis Associated with Castleman’s Disease. Case Rep Gastroenterol 2013; 7: 476-81.

16. Fievet P, Sevestre H, Boudjelal M, Noel LH, Kemeny F, Franco D, Delamarre J, et al. Systemic AA amyloidosis induced by liver cell adenoma. Gut 1990; 31: 361-3.

17. Thysell H, Ingvar C, Gustafson T, Holmin T. Systemic reactive amyloidosis caused by hepatocellular adenoma. A case report. J Hepatol 1986; 2: 450-7.

18. Shibasaki T, Matsumoto H, Watabe K, Joh K, Nakano H, Matsuda H, Gomi H, et al. A case of renal amyloidosis associated with hepatic adenoma: the pathogenetic role of tumor necrosis factor-alpha. Nephron 1997; 75: 350-3.

19. Cosme A, Horcajada JP, Vidaur F, Ojeda E, Torrado J, Arenas JI. Systemic AA amyloidosis induced by oral contraceptive- associated hepatocellular adenoma: a 13-year follow up. Liver 1995; 15: 164-7.

20. Bioulac-Sage P, Rebouissou S, Thomas C, Blanc J-F, Saric J, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46: 740-8.

21. Lachmann HJ, Gilbertson JA, Gillmore JD, Hawkins PN, Pepys MB. Unicentric Castleman’s disease complicated by systemic AA amyloidosis: a curable disease. QJM 2002; 95: 211-8.

22. Chun YS, Calderaro J, Zucman-Rossi J. Synchronous hepatocellular carcinoma and Castleman’s disease: the role of the interleukin-6-signaling pathway. Hepatology 2012; 56: 392-3.

23. Solomon A, Weiss DT, Schell M, Hrncic R, Murphy CL, Wall J, McGavin MD, et al. Transgenic mouse model of AA amyloidosis. Am J Pathol 1999; 154: 1267-72.

24. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004; 314: 363-9.

25. Androulaki A, Giaslakiotis K, Giakoumi X, Aessopos A, Lazaris AC. Localized Castleman’s disease associated with systemic AA amyloidosis. Regression of amyloid deposits after tumor removal. Ann Hematol 2007; 86: 55-7.

26. Perfetti V, Bellotti V, Maggi A, Arbustini E, De Benedetti F, Paulli M, Marinone MG, et al. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman’s disease. Am J Hematol 1994; 46: 189-93.

27. Keven K, Nergizoðlu G, Ateþ K, Erekul S, Orhan D, Ertürk S, Tulunay O, et al. Remission of nephrotic syndrome after removal of localized Castleman’s disease. Am J Kidney Dis 2000; 35: 1207-11.

28. Paydas S, Gonlusen G, Sagliker Y. Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman’s disease. Nephron 1995; 71: 463-4.